VYNE Therapeutics Inc.(VYNE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

VYNE VYNE Therapeutics Inc.

Closed Good Friday 04-17 16:00:00 EDT

1.85

+0.05

+2.49%

盘后1.85

+0.000.00%

16:05 EDT

High1.89	Low1.80	Vol79.30K
Open1.80	D1 Closing1.81	Amplitude4.99%
Mkt Cap27.44M	Tradable Cap18.88M	Total Shares14.83M
T/O145.79K	T/O Rate0.78%	Tradable Shares10.20M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"VYNE","market":"US","secType":"STK","nameCN":"VYNE Therapeutics Inc.","latestPrice":1.85,"timestamp":1744920000000,"preClose":1.805,"halted":0,"volume":79300,"hourTrading":{"tag":"盘后","latestPrice":1.85,"preClose":1.85,"latestTime":"16:05 EDT","volume":2,"amount":3.7,"timestamp":1744920310951},"delay":0,"floatShares":10204647,"shares":14830013,"eps":-0.935311,"marketStatus":"Closed Good Friday","change":0.045,"latestTime":"04-17 16:00:00 EDT","open":1.8,"high":1.89,"low":1.8,"amount":145794.9515,"amplitude":0.049861,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.935311,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"listingDate":1516856400000,"exchange":"NASDAQ","adjPreClose":1.805,"preHourTrading":{"tag":"盘前","latestPrice":1.72,"preClose":1.805,"latestTime":"09:07 EDT","volume":20,"amount":34.4,"timestamp":1744895258506},"postHourTrading":{"tag":"盘后","latestPrice":1.85,"preClose":1.85,"latestTime":"16:05 EDT","volume":2,"amount":3.7,"timestamp":1744920310951},"volumeRatio":0.6502537045843652,"impliedVol":3.8705,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/VYNE","defaultTab":"news","newsList":[{"id":"2520745327","title":"VYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2520745327","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520745327?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 20:00","pubTimestamp":1742472000,"startTime":"0","endTime":"0","summary":"BRIDGEWATER, N.J., March  20, 2025  (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/20/3046158/0/en/VYNE-Therapeutics-to-Participate-in-the-H-C-Wainwright-3rd-Annual-Autoimmune-Inflammatory-Disease-Virtual-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VYNE","BK4007"],"gpt_icon":0},{"id":"2517497914","title":"VYNE Therapeutics Reports Progress in Clinical Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2517497914","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517497914?lang=en_us&edition=full_marsco","pubTime":"2025-03-08 11:57","pubTimestamp":1741406252,"startTime":"0","endTime":"0","summary":"Vyne Therapeutics Inc ( ($VYNE) ) has released its Q4 earnings. Here is a breakdown of the information Vyne Therapeutics Inc presented to its inves...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/vyne-therapeutics-reports-progress-in-clinical-trials?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/vyne-therapeutics-reports-progress-in-clinical-trials?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","VYNE","PRGS","BK4097","LU2065732104.USD"],"gpt_icon":0},{"id":"2517048188","title":"Analysts Offer Insights on Healthcare Companies: VYNE Therapeutics (VYNE), Lexicon Pharmaceuticals (LXRX) and Xtant Medical Holdings (XTNT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2517048188","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517048188?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 19:51","pubTimestamp":1741348303,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on VYNE Therapeutics (VYNE – Research Report), Lexico...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-vyne-therapeutics-vyne-lexicon-pharmaceuticals-lxrx-and-xtant-medical-holdings-xtnt?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-vyne-therapeutics-vyne-lexicon-pharmaceuticals-lxrx-and-xtant-medical-holdings-xtnt?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XTNT","BK4137","BK4139","BK4198","BK4007","VYNE","LXRX","HCSG"],"gpt_icon":0},{"id":"2517648394","title":"VYNE Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag","url":"https://stock-news.laohu8.com/highlight/detail?id=2517648394","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517648394?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 18:15","pubTimestamp":1741342534,"startTime":"0","endTime":"0","summary":"NasdaqCM:VYNE Earnings and Revenue History March 7th 2025. All figures shown in the chart above are for the trailing 12 month  period. Revenue missed analyst estimates by 8.9%. Earnings per share  exceeded analyst estimates by 3.1%.Looking ahead, revenue is forecast to grow 85% p.a. on average during the next 3 years, compared to a 8.6% growth forecast for the Pharmaceuticals industry in the US.The company's shares are down 6.8% from a week ago.Every company has them, and we've spotted   5 warning signs for VYNE Therapeutics   (of which 2 are a bit unpleasant!","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vyne-therapeutics-full-2024-earnings-101534933.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["VYNE"],"gpt_icon":0},{"id":"2517196900","title":"Buy Rating for VYNE Therapeutics Driven by Strong Financial Health and Promising Pipeline Developments","url":"https://stock-news.laohu8.com/highlight/detail?id=2517196900","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517196900?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 02:16","pubTimestamp":1741284962,"startTime":"0","endTime":"0","summary":"LifeSci Capital analyst Rami Katkhuda has maintained their bullish stance on VYNE stock, giving a Buy rating yesterday. Rami Katkhuda’s rating is b...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-for-vyne-therapeutics-driven-by-strong-financial-health-and-promising-pipeline-developments?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-for-vyne-therapeutics-driven-by-strong-financial-health-and-promising-pipeline-developments?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VYNE"],"gpt_icon":0},{"id":"2517553164","title":"VYNE Therapeutics: Strong Financials and Promising Clinical Developments Reinforce Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2517553164","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517553164?lang=en_us&edition=full_marsco","pubTime":"2025-03-06 23:15","pubTimestamp":1741274148,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Joseph Pantginis has maintained their bullish stance on VYNE stock, giving a Buy rating on February 24. Joseph Pantginis ha...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/vyne-therapeutics-strong-financials-and-promising-clinical-developments-reinforce-buy-rating?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/vyne-therapeutics-strong-financials-and-promising-clinical-developments-reinforce-buy-rating?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VYNE"],"gpt_icon":0},{"id":"2517157954","title":"Vyne Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2517157954","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517157954?lang=en_us&edition=full_marsco","pubTime":"2025-03-06 21:31","pubTimestamp":1741267917,"startTime":"0","endTime":"0","summary":"Vyne Therapeutics Inc reports results for the quarter ended December 31 - Earnings SummaryVyne Therapeutics Inc VYNE.OQ reported a quarterly adjusted loss of 28 cents per share for the quarter ended D","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250306:nL5N3PP1BB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VYNE"],"gpt_icon":0},{"id":"2517529651","title":"VYNE Therapeutics Q4 2024 GAAP EPS $(0.28) Beats $(0.30) Estimate, Sales $84.000K Miss $140.000K Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2517529651","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517529651?lang=en_us&edition=full_marsco","pubTime":"2025-03-06 21:12","pubTimestamp":1741266768,"startTime":"0","endTime":"0","summary":"VYNE Therapeutics Q4 2024 GAAP EPS $(0.28) Beats $(0.30) Estimate, Sales $84.000K Miss $140.000K Estimate","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44163813/vyne-therapeutics-q4-2024-gaap-eps-0-28-beats-0-30-estimate-sales-84-000k-miss-140-000k-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"VYNE Therapeutics Q4 2024 GAAP EPS $(0.28) Beats $(0.30) Estimate, Sales $84.000K Miss $140.000K Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VYNE"],"gpt_icon":0},{"id":"2517154140","title":"BRIEF-VYNE Therapeutics FY Revenue USD 501 Thousand","url":"https://stock-news.laohu8.com/highlight/detail?id=2517154140","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517154140?lang=en_us&edition=full_marsco","pubTime":"2025-03-06 21:00","pubTimestamp":1741266046,"startTime":"0","endTime":"0","summary":"BRIEF-VYNE Therapeutics FY Revenue USD 501 Thousand\n\n\nMar 06 (Reuters) - VYNE Therapeutics FY net income USD -39.834 million.\n\nFY basic EPS USD -0.93\nFY EPS from cont ops USD -0.93","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250306:nPLX8EA79E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VYNE"],"gpt_icon":0},{"id":"2517154963","title":"Vyne Therapeutics FY EPS From Cont Ops USD -0.93","url":"https://stock-news.laohu8.com/highlight/detail?id=2517154963","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517154963?lang=en_us&edition=full_marsco","pubTime":"2025-03-06 21:00","pubTimestamp":1741266001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250306:nPLX8EA79E:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VYNE","BK4007"],"gpt_icon":0},{"id":"2517154950","title":"Vyne Therapeutics FY Net Income USD -39.834 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2517154950","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517154950?lang=en_us&edition=full_marsco","pubTime":"2025-03-06 21:00","pubTimestamp":1741266001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250306:nPLX8EA79E:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","VYNE"],"gpt_icon":0},{"id":"2517547161","title":"VYNE Therapeutics Reports 2024 Fourth Quarter and Year-End Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2517547161","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517547161?lang=en_us&edition=full_marsco","pubTime":"2025-03-06 21:00","pubTimestamp":1741266000,"startTime":"0","endTime":"0","summary":"Repibresib gel (VYN201) Phase 2b vitiligo top-line results expected in mid-2025VYN202 Phase 1b psoriasis trial initiated with results anticipated by year-end 2025Expected cash runway into 2H 2026 BRID","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/06/3038147/0/en/VYNE-Therapeutics-Reports-2024-Fourth-Quarter-and-Year-End-Financial-Results-and-Provides-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VYNE","BK4007"],"gpt_icon":0},{"id":"2516265401","title":"EDSA: Raises $15 Million to Advance EB06…","url":"https://stock-news.laohu8.com/highlight/detail?id=2516265401","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516265401?lang=en_us&edition=full_marsco","pubTime":"2025-03-03 21:20","pubTimestamp":1741008000,"startTime":"0","endTime":"0","summary":"Edesa Biotech, Inc.  is planning for a Phase 2 study of its anti-CXCL10 monoclonal antibody for the treatment of moderate-to-severe non-segmental vitiligo patients. Vitiligo is a disease that causes areas of the skin to lose color, with non-segmental vitiligo being characterized by patches appearing on both sides of the body. It is caused when pigment-producing cells  die or stop producing melanin as a result of an autoimmune disease, genetics, or a triggering event .A 2022 publication reported that the estimated prevalence of vitiligo patients in the U.S. is between 1.9 million and 2.8 million . This corresponds to a vitiligo market is projected to reach approximately $1 billion by 2030 . In support of this, the following two transactions show the potential for vitiligo treatments in development:. The company is continuing IND-enabling work in 2025 and has already received approval from Health Canada to conduct a Phase 2 trial. The","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/edsa-raises-15-million-advance-132000910.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","INCY","VYNE","BK4532","BK4550","BK4588","EDSA","BK4007","BK4139"],"gpt_icon":0},{"id":"2513724400","title":"Vyne Therapeutics Inc  expected to post a loss of 30 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2513724400","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513724400?lang=en_us&edition=full_marsco","pubTime":"2025-02-24 22:19","pubTimestamp":1740406746,"startTime":"0","endTime":"0","summary":"Vyne Therapeutics Inc  expected to post a loss of30cents a share - Earnings Preview Vyne Therapeutics Inc VYNE.OQ VYNE.O is expected to show a rise in quarterly revenue when it reports  results on Feb","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250224:nL5N3PF1FG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VYNE"],"gpt_icon":0},{"id":"2512419784","title":"TD Cowen Remains a Buy on VYNE Therapeutics (VYNE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2512419784","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512419784?lang=en_us&edition=full_marsco","pubTime":"2025-02-20 20:37","pubTimestamp":1740055039,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Stacy Ku maintained a Buy rating on VYNE Therapeutics (VYNE – Research Report) today and set a price target of $5.00. The company’...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/td-cowen-remains-a-buy-on-vyne-therapeutics-vyne?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/td-cowen-remains-a-buy-on-vyne-therapeutics-vyne?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4585","BK4207","BK4127","COWN","BK4566","VYNE","TD"],"gpt_icon":0},{"id":"2512841444","title":"Vyne Therapeutics Price Target Maintained With a $5.75/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2512841444","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512841444?lang=en_us&edition=full_marsco","pubTime":"2025-02-20 00:22","pubTimestamp":1739982120,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/VYNE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 19, 2025 11:22 ET (16:22 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VYNE","LENZ"],"gpt_icon":0},{"id":"2512485353","title":"BRIEF-Vyne Therapeutics Initiates Phase 1B Trial Of Vyn202, A Novel Bd2-Selective Oral Bet Inhibitor, In Plaque Psoriasis","url":"https://stock-news.laohu8.com/highlight/detail?id=2512485353","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512485353?lang=en_us&edition=full_marsco","pubTime":"2025-02-19 23:02","pubTimestamp":1739977360,"startTime":"0","endTime":"0","summary":"BRIEF-Vyne Therapeutics Initiates Phase 1B Trial Of Vyn202, A Novel Bd2-Selective Oral Bet Inhibitor, In Plaque PsoriasisFeb 19 (Reuters) - Vyne Therapeutics Inc VYNE.O:VYNE THERAPEUTICS INITIATES PHA","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250219:nTUA53TT1V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VYNE","BK4007"],"gpt_icon":0},{"id":"2512485899","title":"VYNE Therapeutics Receives Buy Rating: Promising Clinical Advances in Plaque Psoriasis Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2512485899","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512485899?lang=en_us&edition=full_marsco","pubTime":"2025-02-19 22:45","pubTimestamp":1739976312,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on VYNE Therapeutics (VYNE – Research Report) today and set a price target of $5.7...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/vyne-therapeutics-receives-buy-rating-promising-clinical-advances-in-plaque-psoriasis-treatment?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/vyne-therapeutics-receives-buy-rating-promising-clinical-advances-in-plaque-psoriasis-treatment?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VYNE"],"gpt_icon":0},{"id":"2512101621","title":"Vyne Therapeutics Initiates Phase 1B Trial of Vyn202, a Novel Bd2-Selective Oral Bet Inhibitor, in Plaque Psoriasis","url":"https://stock-news.laohu8.com/highlight/detail?id=2512101621","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512101621?lang=en_us&edition=full_marsco","pubTime":"2025-02-19 21:00","pubTimestamp":1739970001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250219:nTUA53TT1V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VYNE","BK4007"],"gpt_icon":0},{"id":"2512839104","title":"VYNE Therapeutics Initiates Phase 1b Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis","url":"https://stock-news.laohu8.com/highlight/detail?id=2512839104","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512839104?lang=en_us&edition=full_marsco","pubTime":"2025-02-19 21:00","pubTimestamp":1739970000,"startTime":"0","endTime":"0","summary":"Oral, once-daily doses of VYN202 being evaluated in subjects with moderate-to-severe plaque psoriasis Top-line data from the 12-week double-blind trial expected by year-end 2025 Phase 1b trial designe","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/19/3028700/0/en/VYNE-Therapeutics-Initiates-Phase-1b-Trial-of-VYN202-a-Novel-BD2-Selective-Oral-BET-Inhibitor-in-Plaque-Psoriasis.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","IBD","VYNE"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.vynetherapeutics.com","stockEarnings":[{"period":"1week","weight":0.25},{"period":"1month","weight":0.0511},{"period":"3month","weight":-0.3148},{"period":"6month","weight":-0.1648},{"period":"1year","weight":-0.2292},{"period":"ytd","weight":-0.4478}],"compareEarnings":[{"period":"1week","weight":0.0035},{"period":"1month","weight":-0.0617},{"period":"3month","weight":-0.1191},{"period":"6month","weight":-0.0995},{"period":"1year","weight":0.0517},{"period":"ytd","weight":-0.1018}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":0.045848},{"month":2,"riseRate":0.375,"avgChangeRate":0.008948},{"month":3,"riseRate":0.375,"avgChangeRate":-0.004279},{"month":4,"riseRate":0.25,"avgChangeRate":-0.14041},{"month":5,"riseRate":0.571429,"avgChangeRate":0.038029},{"month":6,"riseRate":0,"avgChangeRate":-0.163623},{"month":7,"riseRate":0.428571,"avgChangeRate":-0.064684},{"month":8,"riseRate":0.142857,"avgChangeRate":-0.080327},{"month":9,"riseRate":0.428571,"avgChangeRate":-0.032924},{"month":10,"riseRate":0.428571,"avgChangeRate":0.003758},{"month":11,"riseRate":0.428571,"avgChangeRate":-0.045576},{"month":12,"riseRate":0.285714,"avgChangeRate":-0.10607}],"exchange":"NASDAQ","name":"VYNE Therapeutics Inc.","nameEN":"VYNE Therapeutics Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"VYNE Therapeutics Inc.(VYNE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest VYNE Therapeutics Inc.(VYNE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"VYNE Therapeutics Inc.,VYNE,VYNE Therapeutics Inc.股票,VYNE Therapeutics Inc.股票老虎,VYNE Therapeutics Inc.股票老虎国际,VYNE Therapeutics Inc.行情,VYNE Therapeutics Inc.股票行情,VYNE Therapeutics Inc.股价,VYNE Therapeutics Inc.股市,VYNE Therapeutics Inc.股票价格,VYNE Therapeutics Inc.股票交易,VYNE Therapeutics Inc.股票购买,VYNE Therapeutics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"VYNE Therapeutics Inc.(VYNE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest VYNE Therapeutics Inc.(VYNE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction